

JUL 24 2003

**SMDA 510(k) SUMMARY**

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21CFR, Part 807, Subpart E, Section 807.92.

**A. GENERAL INFORMATION****1. Applicant**

Olympus Optical Co., Ltd.  
34-3 Hirai Hinode-machi,  
Nishitama-gun, Tokyo, 190-0182  
Japan  
(Registration Number: 3003637092)

**2. Submission Correspondence**

Olympus Optical Co., Ltd.  
2951 Ishikawa-cho Hachioji-shi, Tokyo 192-8507, JAPAN  
TEL: +81-426-42-5129  
FAX: +81-426-42-9979  
(Registration Number: 8010047)

**3. Official Correspondent**

Tina Steffanie-Oak, Senior R.A. Analyst  
Olympus America Inc.  
Two Corporate Center Drive, Melville, NY 11747-3157  
TEL: 631-844-5477  
FAX: 631-844-5416  
(Registration Number: 2429304)

**B. DEVICE IDENTIFICATION****1. Common/Usual Name**

RHINO-LARYNGOVideoscope, its accessories and ancillary equipment

**2. Device Name**

VISERA RHINO-LARYNGOVideoscope OLYMPUS ENF TYPE V, its accessories and ancillary equipment

**3. Classification Name**

CFR Number	Classification Name	Class	Product Code
874.4760	Nasopharyngoscope (flexible) and accessories	II	EOB

**C. IDENTIFICATION OF LEGALLY MARKETED DEVICES WHICH WE CLAIM SUBSTANTIAL EQUIVALENCE**

Model	510(k)#	Manufacturer	Class	Product Code
VISERA Rhino-Laryngovideoscope Olympus ENF type V	#K021073	Olympus Optical Co., Ltd.	II	EOB
EVIS EXERA Bronchovideoscope Olympus BF type 3C160	#K023984	Olympus Optical Co., Ltd.	II	EOQ

**D. DEVICE DESCRIPTION**

**1. Summary**

The subject device, the VISERA Rhino-Laryngovideoscope Olympus ENF type V is identical to the predicate device cleared in #K021073. This premarket notification is submitted to expand the intended use to add compatibility with strobe light sources specified by Olympus and change the applications from the nasal and nasopharyngeal lumens to the nasal lumens and airway anatomy. Olympus specifies the Light Source Model 9100 B and 9100 C (#K921184) manufactured by Kay Elemetrics corp., for endoscopic diagnosis using the strobe light source.

**2. Design**

The VISERA Rhino-Laryngovideoscope Olympus ENF type V has been designed, manufactured and tested in compliance with voluntary safety standards. It meets the requirement of IEC60601-1, IEC60601-1-1, IEC60601-1-2 and IEC60601-2-18.

**3. Materials**

All the patient contacting materials used in this endoscope and ancillary equipment are identical to those used in the devices cleared in the past 510(k) submissions. All materials have been confirmed with ISO 10993-1.

**4. Intended Use of the device**

This instrument has been designed to be used with an OLYMPUS video system center, light source, documentation equipment, display monitor, strobe light source specified by OLYMPUS, and ancillary equipment for endoscopic diagnosis within the nasal lumens and airway anatomy.

**5. Summary including conclusion drawn from Non-clinical Tests**

When compared to the predicate device, the ENF-V does not incorporate any significant changes in the intended use, method of operation, material, or design that could affect safety and effectiveness. Therefore clinical data is not necessary for evaluation of safety and efficacy.



JUL 24 2003

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Olympus Optical Co., Ltd.  
c/o Tina Steffanie-Oak, Senior R.A. Analyst  
Olympus America Inc.  
Two Corporate Center Dr.  
Melville, NY 11747

Re: K031648  
Trade/Device Name: Visera Rhino-Laryngovideoscope Olympus ENF Type V  
Regulation Number: 21 CFR 874.4760  
Regulation Name: Nasopharyngoscope (flexible or rigid) and accessories  
Regulatory Class: Class II  
Product Code: EOB  
Dated: May 23, 2003  
Received: May 28, 2003

Dear Ms. Steffanie-Oak:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4613. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, reading "A. Ralph Rosenthal". The signature is fluid and cursive, with the first name "A." and last name "Rosenthal" clearly legible.

A. Ralph Rosenthal, M.D.  
Director  
Division of Ophthalmic and Ear,  
Nose and Throat Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

510(k) Number (if known): Not assigned yet K031648

Device Name: VISERA RHINO-LARYNGOVideoscope OLYMPUS ENF TYPE V

Indications for Use:

This instrument has been designed to be used with an OLYMPUS video system center, light source, documentation equipment, display monitor, strobe light source specified by OLYMPUS, and ancillary equipment for endoscopic diagnosis within the nasal lumens and airway anatomy.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓

OR

Over-The-Counter Use \_\_\_\_\_

(Per 21 CFR 801.109)

(Optional Format 1-2-96)

Kenneth A. Baker

(Division Sign-Off)  
Division of Ophthalmic Ear,  
Nose and Throat Devices

510(k) Number K031648